Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $57.50B · View financials
Decision snapshot: LGND stock price vs CAH: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CAH's multiple
Needs CAH P/E.
Implied fair value · at LGND's multiple
Needs LGND P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: LGND FY 2025 (ended Dec 31, 2025) · CAH FY 2026 (ended Jun 30, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Capital structure 87% equity / 13% debt · EV / Revenue 0.24x · EV / EBITDA 15.83x
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
LIGAND PHARMACEUTICALS INCORPORATED · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Cardinal Health, Inc. · implied price per share
Bear
$208.52
Base
$255.23
Bull
$319.63
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.37x
-3.08x
Net debt / EBITDA
Leverage against operating earnings
-2.24x
1.04x
Cash and equivalents
Liquid reserves on the balance sheet
$733.52M
$4.86B
Total debt
Interest-bearing obligations outstanding
$374.08M
$8.89B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Royalty Pharma plc
LGND vs RPRX
Sarepta Therapeutics, Inc.
LGND vs SRPT
INCYTE CORP
LGND vs INCY
EXELIXIS, INC.
LGND vs EXEL
MCKESSON CORP
LGND vs MCK
AmerisourceBergen Corporation
LGND vs ABC
Walgreens Boots Alliance, Inc.
LGND vs WBA
CVS Health Corporation
LGND vs CVS
HENRY SCHEIN INC
LGND vs HSIC
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
